NES and non-small cell lung carcinoma: Nestin competes with Nrf2 for binding to Keap1, thereby promoting the production of antioxidant enzymes, enhancing the antioxidant stress resistance in non-small cell lung cancer and gastric cancer, and consequently contributing to drug resistance (30, 31).